|
Market Research Report
Otsuka: Pipeline * Products * Performance * Potential
|
Otsuka:
Pipeline * Products * Performance * Potential published by Espicom Business Intelligence in April, 2008. This report consists of Pages: 80 and the price starts from US $ 1040.
Abstract
Otsuka Pharmaceutical Company (OPC) is one of the largest healthcare companies
in Japan and one of the largest privately-held firms in the world. This report
provides a full review of the company's activities together with sales
forecasts for key products to 2010.
In fiscal 2005, (YE 31st March 2005) Otsuka reported consolidated
pharmaceutical sales of ¥434,100 million. Operating income totalled ¥65,865
million, an increase of 202.2% on the previous year, and net income totalled
¥37,025 million, an increase of 123.72% on the previous year.
Otsuka Pharmaceuticals has eight divisions in total including the
Pharmaceutical business division and the Consumer Products business division.
Expansion of the Pharmaceutical division has been concentrated on Asia and the
Middle East, with the establishment of new clinical R&D laboratories in China
and Thailand, and new drugs launches in South Korea and Vietnam.
R&D Pipeline Overview
- Acalas is for hypertension, angina pectoris and renoparenchymal
hypertension.
- Fijurin for the syndrome of inappropriate secretion of ADH.
- Last-F for the treatment of stomach, breast and lung cancers.
- Toborinone for acute and chronic heart failure, and circulation
insufficiency.
- Vitrase is indicated for diabetic retinopathy.
- Tolvaptan, a non-peptide vasopressin V2-receptor antagonist for the
treatment of congestive heart failure (CHF) and hyponatraemia.
Table of Contents
EXECUTIVE SUMMARY
- Introduction
- Financial performance 2005
- Sales and Market Position
- Income
- Sales, Costs and Operating Income
- Expenditure
- Divisional Performance
- Global Sales by Business Area
- Global Sales by Business Area
- Total Assets by Business Area
- Geographic Performance
- Sales by Destination
- Sales by Destination
- Sales by Origin
- Sales by Origin
- Company strategy
- Mergers, Acquisitions and Divestitures
- Production
- Employees
- Key Agreements
- Product/R&D overview
- Key Products
- Recent Product Launches
- Recent Product Approvals
- R&D Strategy
- Conclusions
PRODUCT PORTFOLIO/RESEARCH & DEVELOPMENT
- R&D Pipeline
- Respiratory - Products
- Major Launched Products
- IPD-1151T
- Key Markets/Indications
- Further Development
- Meptin
- Key Markets/Indications/Formulations
- Competitor Products
- Synaclyn
- UNIPHYL
- Respiratory - summary
- Cardiovascular - Products
- Major Launched Products
- Arkin-Z
- Mode of Action
- Key Markets/Indications/Formulations
- Hi-Z
- Key Markets/Indications/Formulations
- Lorelco
- Mode of Action
- Key Markets/Indications
- Mikelan
- Key Markets/Indications/Formulations
- Further Development
- Pleetal/Pletal
- Mode of Action
- Key Markets/Indications/Formulations
- Further Development
- Competitor Products
- Generic Competition
- Clinical Trial Results
- Sapresta/Bec
- Cardiovascular - R&D
- Acalas
- OPC-28326
- Toborinone
- Tolvaptan
- Cardiovascular - Summary
- Growth Potential
- Limiting Factors
- Gastrointestinal - Products
- Mucosta
- Mode of Action
- Key Markets/Indications/Formulations
- Licensees
- Central Nervous System - Products
- Abilify
- Mode of Action
- Key Markets/Indications/Formulations
- Competitor Products
- Safety Issues
- Clinical Trial Results
- Myocalm
- Central Nervous System - R&D
- Central Nervous System - Summary
- Growth Potential
- Limiting Factors
- Dermatology - Products
- Acuatim
- Mode of Action
- Key Markets/Indications/Formulations
- Urepearl
- Mode of action
- Key Markets/Indications/Formulations
- Dermatology - SUMMARY
- Anticancer - Products
- Abraxane
- Futraful
- Lentinan
- O-gamma 100
- OIF
- Mode of Action
- Key Markets/Indications/Formulations
- S-1 (TS-1)
- Mode of Action
- Key Markets/Indications/Formulations
- Further Development
- Stogar
- UFT
- Anticancer - R&D
- Anticancer - Summary
- Anti-infective - Products
- Herzer
- Kenicef
- Meropen
- Miridacin
- Otsuka CEZ Injection-MC
- Palavale
- Anti-infective - R&D
- Anti-infective - Summary
- Others - Products
- Aminoleban/Aminoleban EN/Kidmin
- BUP-4
- FerriSeltz
- Lepetan
- Neophagen
- Solcoseryl Injection
- Others
- OTHERS - R&D
- OPC-51803
- OPC-6535
- Vitrase
- Others - Summary
APPENDIX 1 - FINANCIAL PERFORMANCE
- Full year results 2005
- Sales, Costs and Operating Income
- Operating Margin (%)
- Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
APPENDIX 2 - KEY CORPORATE EVENTS
APPENDIX 3 - KEY AGREEMENTS
- Abraxis Bioscience Inc
- Astellas Pharma Inc
- Bristol-Myers Squibb
- Oncology agreements
- 17th April 1995
- 6th August 1997
- Aripiprazole Agreement
- 20th September 1999
- Galenea Corporation
- GlaxoSmithKline
- Innovata Biomed Limited
- 20th March 2003
- 5th May 2004
- ISTA Pharmaceuticals Inc
- Merck KGaA
- Methylgene Inc
- Novartis Ophthalmics
- 12th January 1999
- 7th February 2005
- Pfizer
- 30th July 1998
- 28th April 1999
- Prasco Laboratories
- Schwarz Pharma AG
- Sosei Co Ltd
- SRI International
- Toyama Chemical Co Ltd/Nidek Co Ltd
- Vela Pharmaceuticals Inc
- Others
APPENDIX 4 - INFRASTRUCTURE
- Research and development facilities
- Manufacturing facilities
APPENDIX 5 - MAJOR PHARMACEUTICAL
SUBSIDIARIES/JOINT VENTURES
- Subsidiaries
- Joint-venture Companies
APPENDIX 6 - PRODUCT INDEX
|
